Market Research Logo

Global Psoriatic Arthritis Market 2015-2019

Market outlook of the psoriatic arthritis market

Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.

In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.

Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers

The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • TNF inhibitors
  • PDE4 inhibitors
  • Interleukin blockers
  • Others
Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis

The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
  • Mild psoriatic arthritis
  • Moderate psoriatic arthritis
  • Severe psoriatic arthritis
Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals

This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.

Leading vendors in this market are -
  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Celgene
  • UCB
Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.

Key questions answered in the report include
  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the psoriatic arthritis market?
  • What are the key market trends impacting the growth of the psoriatic arthritis market?
  • What are the challenges to market growth?
  • Who are the key vendors in the psoriatic arthritis market?
  • What are the market opportunities and threats faced by the vendors in the psoriatic arthritis market?
  • Trending factors influencing the market shares of APAC, EMEA, and the Americas?
  • What are the key outcomes of the five forces analysis of the psoriatic arthritis market?
Technavio also offers customization on reports based on specific client requirement.

Related reports
  • Global Rheumatoid Arthritis Drugs Market 2014-2018


Press Release

Technavio Announces the Publication of its Research Report – Global Psoriatic Arthritis Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Psoriatic Arthritis Market: Hoffmann-La Roche, Eli-lilly, Sanofi and Otsuka Holdings
Other Prominent Vendors in the market are: Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.
Commenting on the report, an analyst from Technavio’s team said: “Some emerging trends are expected to boost the global psoriatic arthritis market. The dominance of the market by biologics in the treatment of psoriatic arthritis patients is one such trend. It is expected that biologics will be the preferred treatment option of the medical profession as well as the patients themselves. This will increase the number of treatment-seeking patients and result in an increase in the overall consumption of drugs for this condition.”
According to the report, the global psoriatic arthritis market is driven by several factors. The presence of growing unmet needs for appropriate drugs is one of the major factors propelling the growth of the market.
Further, the report states that many branded drugs present for the treatment of psoriatic arthritis are soon going to lose their patent protection. Expiry of patents results in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales. Therefore, this is expected to have a negative impact on the revenue of the branded drugs used to treat psoriatic arthritis.

Companies Mentioned

Hoffmann-La Roche, Eli-lilly, Sanofi, Otsuka Holdings, Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, Celgene.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Product profiles
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Types of psoriatic arthritis
      • Table Types of psoriatic arthritis
    • Symptoms
      • Table Signs and symptoms of psoriatic arthritis
    • Risk factors
      • Table Risk factors for psoriatic arthritis
    • Diagnosis
      • Table Diagnostic test for psoriatic arthritis
    • Disease management
      • Table Treatment options for psoriatic arthritis
      • Table Management of psoriatic arthritis
    • Quality of life
    • Epidemiology
  • Pipeline portfolio
    • Table Pipeline molecules for psoriatic arthritis
    • Table Psoriatic arthritis clinical trial by phase
    • Table Psoriatic arthritis clinical trial by status
  • Novel mechanisms targeted by pipeline candidates
    • Table Novel targets of the pipeline candidates
    • Small molecules
      • Table Tofacitinib
    • Biologics
      • Table Ixekizumab
      • Table Sekukinumab
      • Table Bimekizumab
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global psoriatic arthritis market 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by MoA
    • Table Segmentation of global psoriatic arthritis market by MoA
    • TNF-alpha inhibitors
    • PDE4 inhibitors
    • IL blockers
    • Others
      • Table Segmentation of global psoriatic arthritis market by MoA 2014
  • Market segmentation by type of molecule
    • Table Segmentation of global psoriatic arthritis market by type of molecule
    • Biologics
    • Small molecules
  • Market segmentation by severity of disease
    • Table Segmentation of global psoriatic arthritis market by severity of disease
  • Market segmentation by route of administration
    • Table Segmentation of global psoriatic arthritis market by route of administration
    • Oral
    • Parenteral
    • Topical
  • Market segmentation by dosage form
    • Table Segmentation of global psoriatic arthritis market by dosage form
    • Solid
    • Liquid
    • Semi-solid
  • Geographical segmentation
    • Table Global psoriatic arthritis market by geography 2014
    • Psoriatic arthritis market in Americas
      • Table Psoriatic arthritis market in Americas 2014-2019 ($ millions)
    • Psoriatic arthritis market in EMEA
      • Table Psoriatic arthritis market in EMEA 2014-2019 ($ millions)
    • Psoriatic arthritis market in APAC
      • Table Psoriatic arthritis market in APAC 2014-2019 ($ millions)
      • Table Global psoriatic arthritis market by geography 2014-2019 ($ millions)
  • Market drivers
    • Table Drivers in global psoriatic arthritis market
    • Increase in public awareness
    • Unmet medical needs
    • Growing patient population
    • Change in lifestyle patterns
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Table Challenges in global psoriatic arthritis market
    • Increasing costs of biologics
      • Table Average annual cost of HUMIRA, Enbrel, and Remicade 2014 ($)
    • Loss of patent exclusivity of branded therapies
      • Table Approvals and patent expiries of branded biologics
    • Use of CAM by patients
    • Adverse effects of drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Trends in global psoriatic arthritis market
    • Emergence of biosimilars
    • Popularity of off-label and traditional treatment options
    • Patient assistance programs in the US
    • Dominance of market by biologics
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table YoY sales comparison of top drugs 2010-2014 ($ millions)
      • Table YoY sales comparison of top drugs 2010-2014 (%)
      • Table YoY global sales of HUMIRA 2010-2014 ($ millions)
      • Table AbbVie: Key takeaways
      • Table YoY global sales of Remicade 2010-2014 ($ millions)
      • Table YoY global sales of Simponi 2012-2014 ($ millions)
      • Table Janssen Pharmaceuticals: Key takeaways
      • Table YoY sales of Enbrel in US and Canada 2010-2014 (($ millions)
      • Table YoY sales of Enbrel in US 2010-2014 ($ millions)
      • Table YoY sales of Enbrel in Canada 2010-2014 ($ millions)
      • Table YoY sales of Enbrel in Japan 2010-2014 ($ millions)
      • Table Comparison of YoY sales of Enbrel in US, Japan, and Canada 2010-2014 ($ millions)
      • Table Amgen: Key takeaways
      • Table UCB: Key takeaways
      • Table Celgene: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: Product segmentation by revenue 2014
      • Table AbbVie: Geographical segmentation by revenue 2014
    • Amgen
      • Table Amgen: Business segmentation by revenue 2014
      • Table Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Amgen: Geographical segmentation by revenue 2014
    • Celgene
      • Table Celgene: Product segmentation by revenue 2014
      • Table Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
      • Table Celgene: Geographical segmentation by revenue 2014
    • Janssen Pharmaceuticals
      • Table Janssen Pharmaceuticals: Key therapeutic areas
    • UCB
      • Table UCB: Product segmentation by revenue 2014
      • Table UCB: Product segmentation by revenue 2013 and 2014
      • Table UCB: Geographical segmentation by revenue 2014
      • Table Geographical segmentation by revenue 2013 and 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report